Dr. Min Seob Lee is the CEO, co-founder and co-chairman the board of Diagnomics Inc, in San Diego, CA. He also serves as the co-CEO of the Eone Diagnomics Genome Center (KOSDAQ; EDGC) in Incheon South Korea. He is a visiting professor of Institute of Convergence Science & Technology in Incheon National University and a director of ShareGenome in California that promotes research in precision medicine and scientific discoveries from genomics and health data. Dr. Lee is a writer of the “Homo Hundred Genome Revolution” book and published numerous scientific articles.
Diagnomics is one of the first whole genome sequencing (WGS) based genomics and bioinformatics company with an expertise in personal genome annotation and interpretation for personalized medicine. EDGC is a joint venture between EONE Life Science and Diagnomics, Inc. that focuses on clinical and consumer genomic application development and service offering using next generation sequencing and microarray technology. Dr. Lee has established multiple companies and institutes in Genomics and Personalized Medicine industries globally. He is a world-renowned scholar, researcher and entrepreneur in Genomics and outstanding leader in healthcare and bio-tech industries and its implementation for personalized medicine and diagnostics development for precision medicine. He has extensive global experience and presence in the life sciences, healthcare and IT business area including bio-tech, pharmaceutical and diagnostics companies with expertise in personal genomics, big-data processing, artificial intelligence (AI), pharmacogenomics, bioinformatics and molecular diagnostics. Prior to his current role and responsibilities, he held several positions at Sequenom in San Diego, CA and Genaissance Pharmaceuticals in New Haven, CT within their diagnostic development and genomics lab operations.
He has been granted many US, Korea and international patents in the area of personalized medicine, genomics and diagnostic development. He conducted his post-doctoral fellowship at the Genomics and Proteomics Center at Harvard Medical School and Beth Israel Deaconess Medical Center and received his Ph.D. degree in Biological Science from City of Hope National Medical Center at the Beckman Research Institute in Duarte, CA. He holds a Master of Biology and certification of BioTechnology from California State University, Los Angeles. He graduated as a Bachelor of Science in Biology from Kyung Hee University in Seoul Korea. He also completed an executive MBA program for CEO in Bio-Technology from Seoul National University, Korea.